These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


274 related items for PubMed ID: 19922885

  • 1. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years.
    Block SL, Toback SL, Yi T, Ambrose CS.
    Clin Ther; 2009 Oct; 31(10):2140-7. PubMed ID: 19922885
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
    Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest BD, D153-P504 LAIV Study Group.
    Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.
    Belshe RB, Ambrose CS, Yi T.
    Vaccine; 2008 Sep 12; 26 Suppl 4():D10-6. PubMed ID: 18611422
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
    Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J.
    Vaccine; 2009 Feb 11; 27(7):1101-10. PubMed ID: 19095024
    [Abstract] [Full Text] [Related]

  • 5. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies.
    Ambrose CS, Wu X, Knuf M, Wutzler P.
    Vaccine; 2012 Jan 20; 30(5):886-92. PubMed ID: 22155144
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.
    Vaccine; 2008 Jun 02; 26(23):2841-8. PubMed ID: 18462851
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia.
    Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, Lee BW, Qian Y, Samakoses R, Lolekha S, Rajamohanan KP, Narayanan SN, Kirubakaran C, Rappaport R, Razmpour A, Gruber WC, Forrest BD, Pan-Asian CAIV-T Pediatric Efficacy Trial Network.
    Pediatr Infect Dis J; 2007 Jul 02; 26(7):619-28. PubMed ID: 17596805
    [Abstract] [Full Text] [Related]

  • 8. Duration of protection provided by live attenuated influenza vaccine in children.
    Ambrose CS, Yi T, Walker RE, Connor EM.
    Pediatr Infect Dis J; 2008 Aug 02; 27(8):744-8. PubMed ID: 18600188
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group.
    Pediatr Infect Dis J; 2006 Oct 02; 25(10):860-9. PubMed ID: 17006278
    [Abstract] [Full Text] [Related]

  • 10. A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children.
    Breiman RF, Brooks WA, Goswami D, Lagos R, Borja-Tabora C, Lanata CF, Londoño JA, Lum LC, Rappaport R, Razmpour A, Walker RE, Gruber WC, Forrest BD.
    Vaccine; 2009 Sep 04; 27(40):5472-9. PubMed ID: 19616493
    [Abstract] [Full Text] [Related]

  • 11. Live attenuated versus inactivated influenza vaccine in infants and young children.
    Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM, CAIV-T Comparative Efficacy Study Group.
    N Engl J Med; 2007 Feb 15; 356(7):685-96. PubMed ID: 17301299
    [Abstract] [Full Text] [Related]

  • 12. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care.
    Vesikari T, Fleming DM, Aristegui JF, Vertruyen A, Ashkenazi S, Rappaport R, Skinner J, Saville MK, Gruber WC, Forrest BD, CAIV-T Pediatric Day Care Clinical Trial Network.
    Pediatrics; 2006 Dec 15; 118(6):2298-312. PubMed ID: 17142512
    [Abstract] [Full Text] [Related]

  • 13. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM, Yi T, Ambrose CS.
    Vaccine; 2011 Jun 10; 29(26):4322-7. PubMed ID: 21513761
    [Abstract] [Full Text] [Related]

  • 14. Live attenuated influenza vaccine in children.
    Ambrose CS, Walker RE, Connor EM.
    Semin Pediatr Infect Dis; 2006 Oct 10; 17(4):206-12. PubMed ID: 17055372
    [Abstract] [Full Text] [Related]

  • 15. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T, Karvonen A, Smith HM, Dunning A, Razmpour A, Saville MK, Gruber WC, Forrest BD.
    Pediatrics; 2008 Mar 10; 121(3):e568-73. PubMed ID: 18299305
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.
    Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB.
    Pediatr Infect Dis J; 2012 Jul 10; 31(7):745-51. PubMed ID: 22466322
    [Abstract] [Full Text] [Related]

  • 17. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.
    Pediatrics; 2005 Aug 10; 116(2):e285-94. PubMed ID: 16061582
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial.
    LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC, Bettis R, Kudule L, Harris J, Yates P, Tisdale M, Webster A.
    Clin Ther; 2007 Aug 10; 29(8):1579-90; discussion 1577-8. PubMed ID: 17919541
    [Abstract] [Full Text] [Related]

  • 19. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL, Yogev R, Hayden FG, Ambrose CS, Zeng W, Walker RE.
    Vaccine; 2008 Sep 08; 26(38):4940-6. PubMed ID: 18662737
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.
    Vaccine; 2011 Nov 21; 29(50):9391-7. PubMed ID: 21983154
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 14.